Concepedia

Dmitry Zamoryakhin

DZ

Statistics

Publications

10

Citations

620

H-Index

10

Active since

2014

Affiliations

Daiichi Sankyo (United Kingdom)(Current)

University of Alberta

University of Edinburgh

Centre for Chronic Disease Control

Clinical Research Institute

Dmitry Zamoryakhin is an author at Daiichi Sankyo (United Kingdom) specializing in medicine, cardiology, and cardiovascular pharmacotherapy.

ORCID

Publications per year

2014–2018

10

Publications

10

Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial

Andreas Goette, José Luís Merino, Michael D. Ezekowitz et al. · The Lancet · 2016 · 246 citations

, , +12

A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events

Matthew M. Heeney, Carolyn Hoppe, Miguel R. Abboud et al. · New England Journal of Medicine · 2015 · 145 citations · Full text

, , +17

Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: Insights from the TRILOGY ACS Trial

Chiara Melloni, Jan H. Cornel, Gail E. Hafley et al. · European Heart Journal Acute Cardiovascular Care · 2015 · 60 citations · Full text

, , +17

A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study

Gregory Y.H. Lip, José Luís Merino, Michael D. Ezekowitz et al. · American Heart Journal · 2015 · 32 citations · Full text

, , +10

Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: Insights from the TRILOGY ACS trial

Jan H. Cornel, E. Magnus Ohman, Benjamin Neely et al. · American Heart Journal · 2014 · 30 citations

, , +17

1–5 of 10